| Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia DL Porter, BL Levine, M Kalos, A Bagg, CH June New England Journal of Medicine 365 (8), 725-733, 2011 | 4420 | 2011 |
| Chimeric antigen receptor–modified T cells for acute lymphoid leukemia SA Grupp, M Kalos, D Barrett, R Aplenc, DL Porter, SR Rheingold, ... New England Journal of Medicine 368 (16), 1509-1518, 2013 | 4037 | 2013 |
| T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June Science translational medicine 3 (95), 95ra73-95ra73, 2011 | 3145 | 2011 |
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV P Tebas, D Stein, WW Tang, I Frank, SQ Wang, G Lee, SK Spratt, ... New England Journal of Medicine 370 (10), 901-910, 2014 | 1721 | 2014 |
| Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma GP Linette, EA Stadtmauer, MV Maus, AP Rapoport, BL Levine, L Emery, ... Blood, The Journal of the American Society of Hematology 122 (6), 863-871, 2013 | 1210 | 2013 |
| Monoclonal TCR-redirected tumor cell killing N Liddy, G Bossi, KJ Adams, A Lissina, TM Mahon, NJ Hassan, J Gavarret, ... Nature medicine 18 (6), 980-987, 2012 | 1003 | 2012 |
| NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, ... Nature medicine 21 (8), 914-921, 2015 | 969 | 2015 |
| Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies GL Beatty, AR Haas, MV Maus, DA Torigian, MC Soulen, G Plesa, ... Cancer immunology research 2 (2), 112-120, 2014 | 908 | 2014 |
| Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells J Scholler, TL Brady, G Binder-Scholl, WT Hwang, G Plesa, KM Hege, ... Science translational medicine 4 (132), 132ra53-132ra53, 2012 | 762 | 2012 |
| Identification of a titin-derived HLA-A1–presented peptide as a cross-reactive target for engineered MAGE A3–directed T cells BJ Cameron, AB Gerry, J Dukes, JV Harper, V Kannan, FC Bianchi, ... Science translational medicine 5 (197), 197ra103-197ra103, 2013 | 707 | 2013 |
| Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells JA Fraietta, CL Nobles, MA Sammons, S Lundh, SA Carty, TJ Reich, ... Nature 558 (7709), 307-312, 2018 | 689 | 2018 |
| Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, ... Blood, The Journal of the American Society of Hematology 121 (26), 5154-5157, 2013 | 661 | 2013 |
| T cells expressing chimeric antigen receptors can cause anaphylaxis in humans MV Maus, AR Haas, GL Beatty, SM Albelda, BL Levine, X Liu, Y Zhao, ... Cancer immunology research 1 (1), 26-31, 2013 | 657 | 2013 |
| Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans MC Jensen, L Popplewell, LJ Cooper, D DiGiusto, M Kalos, JR Ostberg, ... Biology of blood and marrow transplantation 16 (9), 1245-1256, 2010 | 643 | 2010 |
| Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology M Kalos, CH June Immunity 39 (1), 49-60, 2013 | 608 | 2013 |
| Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, ... The Journal of clinical investigation 126 (10), 3814-3826, 2016 | 585 | 2016 |
| RNA-based gene therapy for HIV with lentiviral vector–modified CD34+ cells in patients undergoing transplantation for AIDS-related lymphoma DL DiGiusto, A Krishnan, L Li, H Li, S Li, A Rao, S Mi, P Yam, S Stinson, ... Science translational medicine 2 (36), 36ra43-36ra43, 2010 | 508 | 2010 |
| Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells S Gill, SK Tasian, M Ruella, O Shestova, Y Li, DL Porter, M Carroll, ... Blood, The Journal of the American Society of Hematology 123 (15), 2343-2354, 2014 | 499 | 2014 |
| Use of chimeric antigen receptor-modified T-cells to treat cancer CH June, BL Levine, DL Porter, MD Kalos, MC Milone US Patent 9,499,629, 2016 | 443 | 2016 |
| The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade DA Schaer, RP Beckmann, JA Dempsey, L Huber, A Forest, N Amaladas, ... Cell reports 22 (11), 2978-2994, 2018 | 370 | 2018 |
